The effect of combining antitubulin agents on differentiated and undifferentiated human colon cancer cells

被引:21
作者
Carles, G [1 ]
Braguer, D [1 ]
Sabeur, G [1 ]
Briand, C [1 ]
机构
[1] Fac Pharm, CNRS, UPRES A6032, F-13005 Marseille 5, France
关键词
cell differentiation; docetaxel; low concentrations; paclitaxel; sequential combination; vinorelbine;
D O I
10.1097/00001813-199803000-00003
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The cytotoxicity of sequential combinations of a taxoid [paclitaxel (TAX) or docetaxel (TXT)] with a vinca alkaloid [vinorelbine (NVB)] was compared in differentiated and undifferentiated HT29-D4 cells. Agents were titrated from low doses inducing no modification of microtubule network to high doses corresponding to the clinically relevant concentrations that block mitosis. For undifferentiated cells, the sequential combination NVB/TAX was more efficient than TAX/NVB (22% cell survival versus 37% for 5 nM TAX and NVB). Surprisingly, we successively obtained synergism for low doses of both compounds [NVB (1-5 nM) and TAX (1- 15 nM)], then additivity and finally antagonism when one of the compounds was at the concentration inducing mitotic block. The three patterns of results were also obtained with NVB/TXT combinations. For the synergistic combinations at the lowest concentrations, cytotoxicity occurred by apoptosis following mitosis. For differentiated cells, the most cytotoxic combinations were 1 mu M TAX or TXT for 3 days followed by 1 mu M NVB for 3 days, and 0.75 nM TAX or TXT for 9 days followed by 1 mu M NVB for 3 days, the latter producing synergistic effects. Cytotoxicity occurred by apoptosis for the two states of differentiation. Major differences depending on cell phenotype were demonstrated: low sensitivity of differentiated cells to antitubulin agents and the difference in apoptotic pathways since mitosis is not involved in differentiated cells. [(C) 1998 Rapid Science Ltd.].
引用
收藏
页码:209 / 221
页数:13
相关论文
共 54 条
  • [1] BHALLA K, 1993, LEUKEMIA, V7, P563
  • [2] Bissery MC, 1995, SEMIN ONCOL, V22, P3
  • [3] Blagosklonny MV, 1997, CANCER RES, V57, P130
  • [4] BOXDON BJ, 1987, CANCER RES, V47, P1621
  • [5] Chang AY, 1996, SEMIN ONCOL, V23, P19
  • [6] CELLULAR MICROTUBULES HETEROGENEOUS IN THEIR CONTENT OF MICROTUBULE-ASSOCIATED PROTEIN-4 (MAP4)
    CHAPIN, SJ
    BULINSKI, JC
    [J]. CELL MOTILITY AND THE CYTOSKELETON, 1994, 27 (02): : 133 - 149
  • [7] COMPUTERIZED QUANTITATION OF SYNERGISM AND ANTAGONISM OF TAXOL, TOPOTECAN, AND CISPLATIN AGAINST HUMAN TERATOCARCINOMA CELL-GROWTH - A RATIONAL APPROACH TO CLINICAL PROTOCOL DESIGN
    CHOU, TC
    MOTZER, RJ
    TONG, YZ
    BOSL, GJ
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1994, 86 (20): : 1517 - 1524
  • [8] DANESI R, 1995, MOL PHARMACOL, V47, P1106
  • [9] Davis PK, 1997, J NEUROCHEM, V68, P2338
  • [10] CHARACTERIZATION OF A NAVELBINE-RESISTANT BLADDER-CARCINOMA CELL-LINE CROSS-RESISTANT TO TAXOIDS
    DEBAL, V
    ALLAM, N
    MORJANI, H
    MILLOT, JM
    BRAGUER, D
    BREILLOUT, F
    MANFAIT, M
    [J]. BRITISH JOURNAL OF CANCER, 1994, 70 (06) : 1118 - 1125